FBLG — Fibrobiologics Balance Sheet
0.000.00%
Annual balance sheet for Fibrobiologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.407 | 2.27 | 9.16 | 14 | 4.89 |
| Net Total Receivables | — | 0.3 | 0 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.468 | 2.63 | 9.21 | 14.2 | 6.35 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 2.2 | 2.61 | 2.22 | 3.22 |
| Other Long Term Assets | |||||
| Total Assets | 0.468 | 4.82 | 11.8 | 16.4 | 9.62 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.76 | 7.07 | 9.18 | 12.7 | 1.76 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.76 | 8.82 | 10.6 | 13.7 | 3.46 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -1.29 | -4 | 1.25 | 2.73 | 6.16 |
| Total Liabilities & Shareholders' Equity | 0.468 | 4.82 | 11.8 | 16.4 | 9.62 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |